Selective mTORC1 Inhibitors to Treat TSC

Abstract

mTOR (mammalian target of rapamycin) is a protein kinase that forms two distinct complexes mTORC1 and mTORC2. Aberrant upregulation of mTORC1 signaling has the potential to cause disease, including Tuberous Sclerosis Complex (TSC). We aim to develop novel mTORC1 inhibitors with improved potency and safety over current mTORC1 inhibitors in the market, such as Rapamycin and Everolimus (a rapamycin analog). After initial high throughput screening, we have obtained a class of molecules that inhibit mTORC1 in vitro with a different mode of action than Rapamycin. We are currently optimizing this class of molecules towards activity towards mTORC1 inhibition in cells and in mouse models.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2023
Accession Number
AD1208652

Entities

People

  • Dritan Liko
  • Michael N. Hall

Organizations

  • University of Basel

Tags

DTIC Thesaurus Topics

  • Analogs
  • Biomedical Research
  • Cell Line
  • Cells
  • Cultured Cells
  • Diseases
  • Inhibition
  • Inhibitors
  • Instructions
  • Maryland
  • Molecules
  • Neoplasms
  • Optimization
  • Phosphorylation
  • Professional Development
  • Small Molecules
  • Tumor Cell Line

Fields of Study

  • Chemistry
  • Medicine

Readers

  • Aquatic Ecology
  • Breast cancer cell signaling and growth regulation.
  • Oncology (Cancer Research).